Sarepta Gets Clearance From UK's MHRA To Continue Dosing In ENVISION Study Of Elevidys In DMD
21/5 15:26
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Wednesday said that the UK's Medicines & Healthcare products Regulatory Agency (MHRA) has given clearance to continue dosing in the ENVISION Study of its gene therapy Elevidys for the treatment of Duchenne Muscular Dystrophy....